Facebook-f Twitter Tiktok Instagram Youtube
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

QURE – uniQure N.V.

Float Short %

14.68

Margin Of Safety %

Put/Call OI Ratio

0.3

EPS Next Q Diff

0.61

EPS Last/This Y

1.57

EPS This/Next Y

0.69

Price

19.52

Target Price

52.55

Analyst Recom

1.43

Performance Q

31.51

Relative Volume

0.39

Beta

0.67

Ticker: QURE



20 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2025-11-13QURE30.340.370.08199911
2025-11-14QURE29.840.371.41202148
2025-11-17QURE30.310.380.16205481
2025-11-18QURE29.770.380.52208090
2025-11-19QURE27.970.380.45209934
2025-11-20QURE27.60.371.07209286
2025-11-21QURE27.810.320.77203953
2025-11-24QURE27.790.300.46160480
2025-11-25QURE27.910.310.07164017
2025-11-26QURE27.450.304.97169946
2025-12-01QURE26.570.351.04178470
2025-12-02QURE25.320.360.35181823
2025-12-03QURE25.460.370.68182283
2025-12-04QURE22.730.340.44185178
2025-12-05QURE21.330.330.68169530
2025-12-08QURE21.750.340.28168691
2025-12-09QURE20.750.330.29167641
2025-12-10QURE20.150.320.15166871
2025-12-11QURE19.760.310.15166875
2025-12-12QURE19.510.300.29166410
DateSymbolLatestP/C OIP/C VolTotal OI
20 items Current Page1 of 1



20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-11-13QURE30.3454.022.9-2.74
2025-11-14QURE29.8544.128.4-3.33
2025-11-17QURE30.3245.122.0-3.31
2025-11-18QURE29.6945.129.3-3.31
2025-11-19QURE27.9545.137.2-3.31
2025-11-20QURE27.8845.125.9-3.31
2025-11-21QURE27.7845.126.0-3.31
2025-11-24QURE27.7844.725.2-3.31
2025-11-25QURE27.9644.723.6-3.31
2025-11-26QURE27.6044.727.8-3.31
2025-12-01QURE26.5944.732.2-3.31
2025-12-02QURE25.3244.735.4-3.31
2025-12-03QURE25.4844.723.6-3.31
2025-12-04QURE22.7744.749.1-3.31
2025-12-05QURE21.3344.740.3-3.31
2025-12-08QURE21.7744.7- -3.31
2025-12-09QURE20.7844.736.6-3.30
2025-12-10QURE20.1344.933.4-3.30
2025-12-11QURE19.7844.929.9-3.35
2025-12-12QURE19.5244.928.2-3.35
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1



20 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-11-13QURE-4.61-1.6012.63
2025-11-14QURE-4.61-1.6012.63
2025-11-17QURE-4.612.4712.43
2025-11-18QURE-5.222.4712.38
2025-11-19QURE-5.442.4712.38
2025-11-20QURE-5.442.4712.17
2025-11-21QURE-6.442.4712.17
2025-11-24QURE-6.44-6.7512.17
2025-11-25QURE-6.44-6.7512.17
2025-11-26QURE-6.44-6.7514.80
2025-12-01QURE-6.51-6.7914.78
2025-12-02QURE-6.51-6.7914.78
2025-12-03QURE-6.51-6.7914.78
2025-12-04QURE-6.51-6.7914.78
2025-12-05QURE-6.51-6.7914.78
2025-12-08QURE-6.51-6.7414.78
2025-12-09QURE-6.51-6.7414.78
2025-12-10QURE-6.51-6.7414.68
2025-12-11QURE-6.51-6.7414.68
2025-12-12QURE-6.51-6.7414.68
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
20 items Current Page1 of 1

[stock_market_widget type="chart" template="candlestick" assets="QURE" range="1y" interval="1d" price_field="close" heading="{symbol}" candle_border_width="1" candle_bullish_background_color="#21BA45" candle_bearish_background_color="#DB2828" candle_bullish_border_color="#21BA45" candle_bearish_border_color="#DB2828" axes_color="#000000" tooltip_text_color="#262626" tooltip_background_color="#ffffff" range_selector="true" volume_enabled="true" axes_enabled="true" tooltip_enabled="false" zoom_enabled="true" save_image_enabled="true" volume_bar_fill_color="#5679FF" api="yahoo-finance"]

Last Quarter Act. EPS​

-1.38

Avg. EPS Est. Current Quarter

-0.8

Avg. EPS Est. Next Quarter

-0.77

Insider Transactions

-6.51

Institutional Transactions

-6.74

Beta

0.67

Average Sales Estimate Current Quarter

4

Average Sales Estimate Next Quarter

5

Fair Value

Quality Score

40

Growth Score

36

Sentiment Score

32

Actual DrawDown %

72.7

Max Drawdown 5-Year %

-92.2

Target Price

52.55

P/E

Forward P/E

PEG

P/S

76.31

P/B

5.3

P/Free Cash Flow

EPS

-4.39

Average EPS Est. Cur. Y​

-3.35

EPS Next Y. (Est.)

-2.66

Target Price Estimates Raised

Target Price Estimates Lowered

1

Profit Margin

-1492.9

Relative Volume

0.39

Return on Equity vs Sector %

-129.7

Return on Equity vs Industry %

-114.7

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.59

EBIT Estimation

28.2
[stock_market_widget type=”table-options” template=”gradient” color=”#5679FF” assets=”QURE” fields=”contract_symbol,type,strike,price,change_pct,implied_volatility,change_abs,open_interest,volume,in_the_money,bid,ask” pagination=”true” rows_per_page=”21″ sort_direction=”asc” alignment=”left” search=”true” sort_field=”strike” api=”yahoo-finance”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”QURE” options_type=”calls” x_axis_field=”strike” y_axis_field=”price” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”QURE” options_type=”puts” x_axis_field=”strike” y_axis_field=”price” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”QURE” options_type=”calls” x_axis_field=”strike” y_axis_field=”implied_volatility” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”QURE” options_type=”puts” x_axis_field=”strike” y_axis_field=”implied_volatility” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”QURE” options_type=”calls” x_axis_field=”strike” y_axis_field=”volume” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”QURE” options_type=”puts” x_axis_field=”strike” y_axis_field=”volume” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
uniQure N.V.
Sector: Healthcare
Industry: Biotechnology
Employees: 209
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
stock quote shares QURE – uniQure N.V. Stock Price stock today
news today QURE – uniQure N.V. stock forecast ,stock prediction 2023 2024 2025
marketwatch QURE – uniQure N.V. yahoo finance google finance
stock history QURE – uniQure N.V. invest stock market
stock prices QURE premarket after hours
ticker QURE fair value insiders trading